The agency’s decision was based on the outcomes of the double-blind, randomised, sham-controlled RESET-RA study.

The FDA has approved the SetPoint System, a vagus nerve stimulator from SetPoint Medical, for the treatment of rheumatoid ...

SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today ...

SetPoint Medical announced today that the FDA approved its SetPoint neuroimmune modulation system for treating rheumatoid ...

US FDA approves SetPoint Medical’s novel neuroimmune modulation device, SetPoint System for rheumatoid arthritis: Valencia, California Saturday, August 2, 2025, 17:00 Hrs [IST] ...

The FDA has approved a medical device that stimulates the vagus nerve for the treatment of moderate-to-severe rheumatoid ...

A first-of-its-kind implant has just been granted approval from the US Food and Drug Administration (FDA) for the treatment ...

“The new implantable device designed by SetPoint Medical is an exciting development in RA therapy. It is extremely easy to place, with no external battery or wires that need to be connected, and ...

The Food and Drug Administration has approved a vagus nerve bioimplant to treat rheumatoid arthritis (RA). The scientific ...

SetPoint recently initiated a pilot trial evaluating the company's proprietary device for treatment of drug-refractory RA patients in the U.S.

Setpoint Medical Corp. reported positive topline results from its landmark RESET-RA study. The study evaluated the Setpoint system as a potential new neuroimmune modulation treatment for adults living ...

Setpoint Medical Corp. reported positive topline results from its landmark RESET-RA study. The study evaluated the Setpoint system as a potential new neuroimmune modulation treatment for adults living ...